Gyre Therapeutics vs Arcus Biosciences
GYRE and RCUS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GYRE and RCUS compare
Arcus Biosciences is the larger company, worth 4.1 times as much as Gyre Therapeutics ($2.1B against $508M).
Gyre Therapeutics grew revenue faster over the last twelve months (−3.7% versus −55.3% for Arcus Biosciences).
Gyre Therapeutics keeps more of each dollar of sales as profit, with a net margin of −33.9% compared with −393% at Arcus Biosciences.
Gyre Therapeutics scores higher on the StockData Score (11 against 3 for Arcus Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GYRE | RCUS |
|---|---|---|
| Size and price | ||
| Market cap | $508M | $2.1B |
| Share price | $4.56 | $16.39 |
| Change, 1 year | −42.9% | −18.3% |
| Change, 5 years | −75.7% | −64.6% |
| Beta (5Y) | 1.21 | 1.13 |
| Employees | 618 | 601 |
| StockData Score | ||
| Total score | 11 (better) | 3 |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 3 (better) | 0 |
| Health score | 6 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 4.7× (better) | 17.8× |
| P/B | 4.7× | 4.5× (better) |
| FCF yield | −1.5% (better) | −22.8% |
| Fair value | $5.29 | $7.34 |
| Margin of safety | 13.8% (better) | −123% |
| Growth | ||
| Revenue growth (TTM) | −3.7% (better) | −55.3% |
| Revenue growth, 5Y average | 41.0% (better) | 25.9% |
| Net income growth (TTM) | −801% | – |
| Profitability | ||
| Gross margin | 93.4% | – |
| Operating margin | −14.4% (better) | −415% |
| Net margin | −33.9% (better) | −393% |
| FCF margin | −7.2% (better) | −406% |
| Return on equity | −34.9% (better) | −90.8% |
| Return on invested capital | −26.6% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −44.2× |
| Current ratio | 4.32 (better) | 3.82 |
| Altman Z-score | 8.53 (better) | −0.74 |
| Piotroski F-score | 5 (better) | 1 |
| Dividends and buybacks | ||
| Buyback yield | – | −13.8% |
| Shareholder yield | 0.00% (better) | −13.8% |
| Ownership | ||
| Held by institutions | 7.8% | 96.3% |
| Held by insiders | 93.8% | 31.7% |
| Insider net buying, 12 months | −$953K (better) | −$9.3M |
| Short interest, % of float | 32.4% | 15.2% |
Go deeper
- GYRE stock overview
- GYRE income statement
- GYRE valuation and score
- RCUS stock overview
- RCUS income statement
- RCUS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.